CELLTRION-HEALTHCARE
19.5.2023 00:02:32 CEST | Business Wire | Press release
Celltrion Healthcare has partnered with a leading patient organisation, the European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA), to raise awareness of inflammatory bowel disease (IBD) this World IBD Day (19 May 2023).
The campaign, Where’s CC? (Crohn’s and Colitis), aims to spark conversations about the impact of IBD across people’s lives and how these challenges vary between different age groups.
People are being encouraged to find the hidden CC characters and learn more about the unique challenges they have faced from being diagnosed with IBD to finding a treatment that works for them, at different stages of life, based on real-life patient insights.
Over ten million people worldwide are living with IBD1, a group of conditions including Crohn’s disease and ulcerative colitis (UC). IBD is most commonly diagnosed between the ages of 10 and 401, however it can appear at any point during people’s lives, with 10% to 15% of newly diagnosed cases of IBD being over the age of 60.2
Clinical research, education and understanding however do not reflect this, leaving groups of people feeling left behind and underrepresented. This can impact patient’s ability to benefit from innovative treatment options and high-quality care, impacting their quality of life and disease outcomes.
Visit www.WhereisCC.com to learn more about the campaign and help in shining a light on IBD by finding CC and learning more about their unique experiences.
Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare, said: “Every IBD patient, no matter their age, deserves to feel understood and have access to high quality care and effective, innovative treatments. Innovations in treatments, including advances in treatment administration that enable people to access at-home injectable treatment allows people to have an improved quality of life whilst managing their condition. We are extremely proud to launch the Where’s CC? campaign in collaboration with EFCCA for World IBD Day 2023 to improve understanding of IBD and the challenges that are associated with specific stages of life.
“Through our partnership with EFCCA, we have unparalleled opportunity to turn the tide in IBD and ensure no patient feels alone or left behind in their unique journey.”
Salvo Leone, EFCCA Chairman, commented: “IBD has no age, yet people living with IBD are facing challenges associated with their age that prevent them benefitting from the best treatment options.
“This World IBD Day, we are delighted to have partnered with Celltrion Healthcare to spotlight some of these challenges to raise awareness and improve care for IBD patients across the world. The Where’s CC? campaign includes important patient resources, and we encourage everyone to spread the word as we work towards a situation where all IBD patients can have a good quality of life.”
Molly O’Donoghue, UC patient, said: “Being diagnosed with UC at 15, I thought I would never be able to move away to university or go travelling with my friends. I was on a downward spiral, becoming depressed and isolated, until I found an at-home treatment that gave me a new freedom to do these things as I had always wanted.
“It is so important that people with IBD are not ashamed of their condition, and we talk about the challenges that come with learning to live with the condition at different stages of life. The Where’s CC? campaign is a brilliant way to raise awareness and help people to overcome the challenges that IBD brings.”
- ENDS -
Notes to Editors:
About Inflammatory Bowel Disease (IBD)
IBD is an umbrella term used to describe conditions including Crohn’s disease and UC. Collectively, IBD impacts over ten million people worldwide.1
IBD is a long-term condition and there may be times when the symptoms are severe, known as a flare-up, and times where there are no or few symptoms, known as remission. Symptoms can be debilitating if the condition is not well managed. These often include abdominal pain and cramping, diarrhoea, weight loss and extreme tiredness.3
Treatment for IBD can be transformative in patients’ lives, reducing the impact of the condition on their lives by minimising flare-up of symptoms and maintaining remission. In recent years, the increasing availability of new treatments has transformed IBD patient care. Innovations in treatments, including advances in treatment administration that enable people to access at-home injectable treatment (versus hospital-based treatment), allows people to have an improved quality of life whilst managing their condition.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit: https://www.celltrionhealthcare.com
About EFCCA
The European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) represents 46 national Crohn’s and ulcerative colitis (collectively known as Inflammatory Bowel Disease or IBD) patient associations. We are an organization of people united in our commitment to improve the life of over 10 million people living with IBD worldwide (3.4 million in Europe alone) and to give them a louder voice and more visibility. For more information, please visit: https://efcca.org/
References
1 EFCCA. What is IBD? Available at: https://efcca.org/content/what-ibd [Accessed May 2023]
2 EFCCA. World IBD Day 2023. Available at: https://efcca.org/projects/world-ibd-day-2023 [Accessed May 2023]
3 NHS. Inflammatory bowel disease. Available at: https://www.nhs.uk/conditions/inflammatory-bowel-disease/ [Accessed May 2023]
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005512/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom